6533b82ffe1ef96bd1295cd8

RESEARCH PRODUCT

Thirty-one novel biomarkers as predictors for clinically incident diabetes.

Blankenberg StefanThomas MuenzelArpo AromaaVeikko SalomaaPekka JousilahtiAki S. HavulinnaTanja ZellerAlun EvansKuulasmaa KariAntti JulaOlli Saarela

subject

AdultMaleRiskmedicine.medical_specialtyDiabetes riskPublic Health and Epidemiologylcsh:Medicine030209 endocrinology & metabolism030204 cardiovascular system & hematologyCohort Studies03 medical and health sciences0302 clinical medicineSex FactorsPredictive Value of TestsDiabetes mellitusInternal medicinemedicineDiabetes MellitusHumansCardiovascular Disorders/Vascular Biologylcsh:ScienceAgedApolipoproteins BProportional Hazards ModelsMultidisciplinaryAdiponectinbiologyProportional hazards modelbusiness.industrylcsh:RC-reactive proteinMiddle Agedmedicine.disease3. Good healthDiabetes and EndocrinologyC-Reactive ProteinROC CurveRelative riskImmunologyCohortFerritinsbiology.proteinlcsh:QFemaleAdiponectinbusinessBiomarkersCohort studyResearch Article

description

Background The prevalence of diabetes is increasing in all industrialized countries and its prevention has become a public health priority. However, the predictors of diabetes risk are insufficiently understood. We evaluated, whether 31 novel biomarkers could help to predict the risk of incident diabetes. Methods and Findings The biomarkers were evaluated primarily in the FINRISK97 cohort (n = 7,827; 417 cases of clinically incident diabetes during the follow-up). The findings were replicated in the Health 2000 cohort (n = 4,977; 179 cases of clinically incident diabetes during the follow-up). We used Cox proportional hazards models to calculate the relative risk of diabetes, after adjusting for the classic risk factors, separately for each biomarker. Next, we assessed the discriminatory ability of single biomarkers using receiver operating characteristic curves and C-statistics, integrated discrimination improvement (IDI) and net reclassification improvement (NRI). Finally, we derived a biomarker score in the FINRISK97 cohort and validated it in the Health 2000 cohort. A score consisting of adiponectin, apolipoprotein B, C-reactive protein and ferritin almost doubled the relative risk of diabetes in the validation cohort (HR per one standard deviation increase 1.88, p = 2.8 e-5). It also improved discrimination of the model (IDI = 0.0149, p<0.0001) and reclassification of diabetes risk (NRI = 11.8%, p = 0.006). Gender-specific analyses suggested that the best score differed between men and women. Among men, the best results were obtained with the score of four biomarkers: adiponectin, apolipoprotein B, ferritin and interleukin-1 receptor antagonist, which gave an NRI of 25.4% (p<0.0001). Among women, the best score included adiponectin, apolipoprotein B, C-reactive protein and insulin. It gave an NRI of 13.6% (p = 0.041). Conclusions We identified novel biomarkers that were associated with the risk of clinically incident diabetes over and above the classic risk factors. This gives new insights into the pathogenesis of diabetes and may help with targeting prevention and treatment.

10.1371/journal.pone.0010100https://pubmed.ncbi.nlm.nih.gov/20396381